WHO WE ARE
We love inspiring the bioscience leaders of tomorrow.
​
We are the world's first Intangible Asset Management Advisory focused exclusively on biosciences. We love doing stellar work for stellar clients all over the world, all while having as much fun and adventure as possible! We realise that these are not typical values for an Intellectual Property or Intangible Asset firm, but we believe that our very nature as human beings is centred around these unique attributes. We enjoy helping clients identify, protect, and monetise their original IP, and this is reflected in the quality of our work and our enthusiasm for life sciences. Our team is small, but delivers high-impact insights along the value chain in bioscience innovation - from innovation, stage-gating, IP strategy, Intangible Asset security and protection, to market evaluation, product creation, and IPO. Our experts have worked with Fortune 500 companies, governments, and biosciences startups at many different parts in their journeys.
Carel Smit - Founder & CEO
Carel Smit is the founder and managing director of Biophile. ​A Cambridge-educated life sciences patent attorney and medtech entrepreneur with masters degrees in genetics, law, and management, he has more than 20 years of experience in bioscience IP, Intangible Asset development, and commercialisation in Australia and abroad. As a former S&P Global 100 in-house IP counsel, he understands the pressures on innovators and IP counsel, mixed with the interplay of commercial objectives. Having also co-founded an award-winning medical devices company that has helped patients in more than 15 countries, he also appreciates the pressures on founders.
​
Carel has served clients in numerous countries and for local clients Carel's knowledge and training in biotechnology, digital health, cell and gene therapy, virology, and biochemistry mean that he is comfortable with many different types of life sciences technologies, either when consulting, assisting with capital raising, or advising on Intangible Asset monetisation strategies. His IP, commercialisation, and BD strategies have been featured by Forbes, the Australian Institute of Company Directors, ABC, and the Australian federal government.
Dr Nigel Chen-Tan - IP Strategy & Analytics
Intellectual Property Strategist | Patent and Trade Marks Attorney (AU/NZ) | Physicist & Materials Scientist - Australia
Nigel is a registered Australia and New Zealand patent and trade marks attorney with a passion for empowering businesses to maximise their intellectual property potential. With a background in applied physics and material science, Nigel combines his technical expertise with over a decade of experience in intellectual property law. He specialises in assisting start-ups and SMEs in the manufacturing sector, providing tailored IP strategies that drive business growth and innovation.
Nigel offers a personalised approach to IP management, guiding clients through identifying, protecting, and commercialising their innovations. Whether it’s preparing IP applications or developing long-term business strategies, Nigel is dedicated to helping his clients achieve their commercial goals.
Dr Amanda Stenbaek - Life Sciences Consultant
Life sciences consultant - UK & Denmark
Amanda is a former medical doctor and venture capital investor with experience spanning biotech, medical devices and digital health. She was investing on the healthcare team at Inkef, a 500M EUR VC fund based in Amsterdam investing in early-stage healthcare and tech startups. She was also a board observer for 6 portfolio companies, including Calypso Biotech and Cardior which were both acquired earlier this year. She has also contributed to industry market reports and mentored academic spinouts in the Benelux region. She has also previously been an investor on the healthcare team at M Ventures, the corporate venture arm of Merck KGaA. Her most recent role was as CBO/entrepreneur in residence at Cirqle Biomedical, a women’s health startup in Copenhagen. Here she supported the team with pipeline expansion, exploring novel indications for their in-house technology and identifying new technology in academia for potential spinouts.
Amanda’s investment experience is complimented by her initial career in medicine, working in a variety of specialties in surgery and medicine both as a medical student and academic foundation doctor in London hospitals. She studied Medicine at Imperial College London, and was awarded 7 distinctions and 4 academic prizes. She also holds a First Class BSc in Surgery & Anaesthesia from Imperial College London, and a MPhil in Bioscience Enterprise from the University of Cambridge.
Xavi Beltri - Life Sciences Consultant
European Market Access, Commercial Strategy & Competitive Intelligence - Switzerland
Xavi is an experienced life sciences strategy consultant with over 8 years of expertise, specialising in market access and commercial strategy. He has led numerous projects across Europe and the US, working with top 10 global pharmaceutical companies. Xavi has developed his career working for top consulting firms such as PwC and IQVIA. His expertise covers early assessment for out-licensing, high level medical strategy, access and reimbursement support, pricing strategy, regulatory evaluation, launch sequencing, product launch strategy, forecasting, investors pitch deck development, omnichannel strategy, due diligence, digital health, loss of exclusivity strategy, and product portfolio analysis
Dr Samuel Lundin - Life Sciences Consultant
Technology Review, Grants, Regulatory - Australia
Samuel is an Immunologist, was a Professor in Biomedicine at University of Gothenburg, Sweden, and was awarded the prestigious EU Marie Curie fellowship to take on a Visiting Professorship at University of Western Australia 2014-2017.
​
Samuel has two decades of academic research leadership in immunology of Helicobacter pylori infection and stomach cancer; he is the sole inventor or co-inventor on the patents of Biotome Pty Ltd. Samuel has deep expertise in: Immunology, immunooncology, bioinformatics, cellular biology, biomarker discovery, preclinical cellular models, diagnostics, commercial strategy, capital raising, and investment case analysis.
Dr Antoine Musu - Innovation Management
Life sciences Innovation Management, Commercialisation, and Marketing - Australia
Antoine is an innovation and marketing professional with a long career prior to academia in diverse ecosystems. He teaches in the MBA, M. Biotechnology, M. Professional Engineering, M. Oceans Leadership Programs, and the B. Agriculture Program at the University of Western Australia's Graduate Business School, where he shares his academic knowledge and real-world professional business experience with students. He has worked in Europe, the Asia Pacific (Singapore, Thailand, Malaysia, Vietnam, and Indonesia), China, Taiwan, and Australia (Melbourne, Sydney, ACT and Perth). Antoine has related experience working with various industries, local government, and regulatory bodies, and held positions as Managing Director/CEO/General Manager in private companies and an ASX-listed company. He has also served on numerous Boards/Committees in Executive and Non-Executive roles.
​
Antoine has a passion for innovation in the biosciences and has deep insights into innovation ecosystems in many different countries. He primarily works with our clients on overarching innovation strategy, intellectual capital capturing, and team based innovation.